Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Neutrexin
Trimetrexate is an antifolate drug used primarily in the treatment of Pneumocystis jirovecii pneumonia (PCP), a common opportunistic infection in individuals with weakened immune systems, such as those with HIV/AIDS. It inhibits dihydrofolate reductase (DHFR), a crucial enzyme in the folate metabolic pathway necessary for DNA synthesis. This action prevents the growth and replication of the Pneumocystis jirovecii parasite.
For the treatment of moderate to severe Pneumocystis jirovecii pneumonia (PCP) in individuals with weakened immune systems.
Outcome:
Decreased efficacy of trimetrexate
Mechanism:
Leucovorin bypasses the DHFR inhibition caused by trimetrexate.
Outcome:
Increased risk of myelosuppression
Mechanism:
May potentiate bone marrow suppression.
Outcome:
May delay absorption
Mechanism:
Unknown
Most likely new formulation: Liposomal trimetrexate for improved efficacy and reduced toxicity (Year: 2026, 60% confidence)
Based on current usage trends and the emergence of alternative treatments, the likelihood of trimetrexate's continued use as a first-line therapy for PCP is projected to decrease by 15% over the next 5 years.
Antineoplastic, Antifolate
2,4-Diaminopteridine